These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31713478)

  • 1. Triggering of Toll-like Receptors in Old Individuals. Relevance for Vaccination.
    Zareian N; Aprile S; Cristaldi L; Ligotti ME; Vasto S; Farzaneh F
    Curr Pharm Des; 2019; 25(39):4163-4167. PubMed ID: 31713478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How Can We Improve Vaccination Response in Old People? Part I: Targeting Immunosenescence of Innate Immunity Cells.
    Aiello A; Ligotti ME; Garnica M; Accardi G; Calabrò A; Pojero F; Arasanz H; Bocanegra A; Blanco E; Chocarro L; Echaide M; Fernandez-Rubio L; Ramos P; Piñeiro-Hermida S; Kochan G; Zareian N; Farzaneh F; Escors D; Caruso C; Candore G
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants.
    Maisonneuve C; Bertholet S; Philpott DJ; De Gregorio E
    Proc Natl Acad Sci U S A; 2014 Aug; 111(34):12294-9. PubMed ID: 25136133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toll-like receptors in older adults.
    van Duin D; Shaw AC
    J Am Geriatr Soc; 2007 Sep; 55(9):1438-44. PubMed ID: 17767688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments.
    Cuzzubbo S; Mangsbo S; Nagarajan D; Habra K; Pockley AG; McArdle SEB
    Front Immunol; 2020; 11():615240. PubMed ID: 33679703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro cytokine induction by TLR-activating vaccine adjuvants in human blood varies by age and adjuvant.
    van Haren SD; Ganapathi L; Bergelson I; Dowling DJ; Banks M; Samuels RC; Reed SG; Marshall JD; Levy O
    Cytokine; 2016 Jul; 83():99-109. PubMed ID: 27081760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Innate Immune Responses of Vaccinees Determine Early Neutralizing Antibody Production After ChAdOx1nCoV-19 Vaccination.
    Shen CF; Yen CL; Fu YC; Cheng CM; Shen TC; Chang PD; Cheng KH; Liu CC; Chang YT; Chen PL; Ko WC; Shieh CC
    Front Immunol; 2022; 13():807454. PubMed ID: 35145520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toll-like Receptor function of murine macrophages, probed by cytokine induction, is biphasic and is not impaired globally with age.
    Pattabiraman G; Palasiewicz K; Ucker DS
    Mech Ageing Dev; 2016 Jul; 157():44-59. PubMed ID: 27453067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies.
    Martinsen JT; Gunst JD; Højen JF; Tolstrup M; Søgaard OS
    Front Immunol; 2020; 11():1112. PubMed ID: 32595636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combinatorial Delivery of Dual and Triple TLR Agonists via Polymeric Pathogen-like Particles Synergistically Enhances Innate and Adaptive Immune Responses.
    Madan-Lala R; Pradhan P; Roy K
    Sci Rep; 2017 May; 7(1):2530. PubMed ID: 28566683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TLR-based immune adjuvants.
    Steinhagen F; Kinjo T; Bode C; Klinman DM
    Vaccine; 2011 Apr; 29(17):3341-55. PubMed ID: 20713100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond.
    Lahiri A; Das P; Chakravortty D
    Vaccine; 2008 Dec; 26(52):6777-83. PubMed ID: 18835576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists.
    Black M; Trent A; Tirrell M; Olive C
    Expert Rev Vaccines; 2010 Feb; 9(2):157-73. PubMed ID: 20109027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The stimulatory effect of the TLR4-mediated adjuvant glucopyranosyl lipid A is well preserved in old age.
    Weinberger B; Joos C; Reed SG; Coler R; Grubeck-Loebenstein B
    Biogerontology; 2016 Feb; 17(1):177-87. PubMed ID: 25957253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TLR based therapeutics.
    Dunne A; Marshall NA; Mills KH
    Curr Opin Pharmacol; 2011 Aug; 11(4):404-11. PubMed ID: 21501972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunologic correlates of protection and potential role for adjuvants to improve influenza vaccines in older adults.
    McElhaney JE; Coler RN; Baldwin SL
    Expert Rev Vaccines; 2013 Jul; 12(7):759-66. PubMed ID: 23885821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical investigations of Toll-like receptor agonists.
    Meyer T; Stockfleth E
    Expert Opin Investig Drugs; 2008 Jul; 17(7):1051-65. PubMed ID: 18549341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant.
    Schaut RG; Grinnage-Pulley TL; Esch KJ; Toepp AJ; Duthie MS; Howard RF; Reed SG; Petersen CA
    Vaccine; 2016 Oct; 34(44):5225-5234. PubMed ID: 27665354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toll or toll-free adjuvant path toward the optimal vaccine development.
    Ishii KJ; Akira S
    J Clin Immunol; 2007 Jul; 27(4):363-71. PubMed ID: 17370119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy.
    Kirtland ME; Tsitoura DC; Durham SR; Shamji MH
    Front Immunol; 2020; 11():599083. PubMed ID: 33281825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.